ARROTEX Pharmaceuticals has announced the Pharmaceutical Benefits Scheme (PBS) listing of ARX-Telmisartan/Amlodipine, a new brand of fixed-dose combination therapy for the management of hypertension.
Available in several different dosages, the drug will be subsidised for adults whose blood pressure is not adequately controlled with monotherapy, providing clinicians with a once-daily combination option that supports long-term cardiovascular risk management.
Fixed-dose combination therapies have been shown to play a role in improving adherence and patient outcomes.
"The PBS listing of ARX-Telmisartan/Amlodipine strengthens our commitment to improving access to high-quality, affordable medicines for Australian patients living with chronic cardiovascular disease," said Hayley Tamborini, Chief Commercial Officer, Arrotex Pharmaceuticals.
"Combination therapies such as this simplify treatment regimens and have been shown to enhance adherence, which is crucial in managing long-term conditions like hypertension," she added.
With the originator and authorised generic brands of the Telmisartan/Amlodipine combination set to be discontinued in coming months, the Arrotex brand provides another alternative for patients, and is a further addition to Arrotex's cardiometabolic medicines portfolio.
"We are strategic in our approach to supply therapies when others can't or won't - we do this to enable continued, sustainable, and affordable access for Australian patients," Stephen Mellett, Arrotex's General Manager of Pharmaceuticals said. KB
The above article was sent to subscribers in Pharmacy Daily's issue from 19 Nov 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 Nov 25
